Jove
Visualize
Contact Us

Related Experiment Videos

Shigellosis.

Swapan Kumar Niyogi1

  • 1National Institute of Cholera and Enteric Diseases P-33, C.I.T. Road, Scheme XM, Beliaghata Kolkata-700 010, India. niyogisk@hotmail.com

Journal of Microbiology (Seoul, Korea)
|May 10, 2005
PubMed
Summary
This summary is machine-generated.

Shigellosis, a severe diarrheal disease, poses a global health threat, particularly in developing countries. Antimicrobial resistance limits treatment options, and vaccine development is ongoing to combat this significant pathogen.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular analysis of multidrug resistance in clinical isolates of <i>Shigella</i> spp. from 2001-2010 in Kolkata, India: role of integrons, plasmids, and topoisomerase mutations.

Infection and drug resistance·2018
Same author

Involvement of topoisomerase mutations and qnr and aac(6')Ib-cr genes in conferring quinolone resistance to clinical isolates of Vibrio and Shigella spp. from Kolkata, India (1998-2009).

Journal of global antimicrobial resistance·2017
Same author

Nasopharyngeal Pneumococcal Colonization and Impact of a Single Dose of 13-Valent Pneumococcal Conjugate Vaccine in Indian Children With HIV and Their Unvaccinated Parents.

The Pediatric infectious disease journal·2017
Same author

Impact of Haemophilus influenzae Type B Conjugate Vaccines on Nasopharyngeal Carriage in HIV-infected Children and Their Parents From West Bengal, India.

The Pediatric infectious disease journal·2016
Same author

Immunogenicity and safety of two doses of catch-up immunization with Haemophilus influenzae type b conjugate vaccine in Indian children living with HIV.

Vaccine·2016
Same author

Salmonella enterica serovar Weltevreden ST1500 associated foodborne outbreak in Pune, India.

The Indian journal of medical research·2015
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Public Health

Background:

  • Shigellosis is a significant global health concern caused by four Shigella species, with Shigella dysenteriae type 1 causing severe illness.
  • Symptoms include bloody diarrhea, abdominal cramps, and tenesmus, resulting from the bacteria invading and destroying colonic epithelial cells.
  • Transmission occurs through contaminated food/water or person-to-person contact, with high morbidity and mortality in children in developing countries.

Purpose of the Study:

  • To provide a comprehensive overview of shigellosis, encompassing its causative agents, pathogenesis, diagnosis, treatment challenges, and current vaccine development efforts.
  • To highlight the global impact of shigellosis, emphasizing its disproportionate effect on young children in developing nations.

Main Methods:

Related Experiment Videos

  • Literature review of shigellosis epidemiology, clinical presentation, diagnostic methods, and therapeutic strategies.
  • Analysis of antimicrobial resistance patterns and the status of vaccine research and development.

Main Results:

  • Shigella species cause dysentery through mucosal invasion, leading to ulceration and bleeding.
  • Antimicrobial treatment is challenged by widespread drug resistance, necessitating newer agents like azithromycin and cephalosporin derivatives.
  • No vaccines are currently available, but candidates targeting S. dysenteriae type 1 and S. flexneri type 2a are under development.

Conclusions:

  • Shigellosis remains a critical public health issue, especially in resource-limited settings, demanding effective control strategies.
  • Addressing antimicrobial resistance and advancing vaccine development are crucial for mitigating the global burden of shigellosis.